The short version
5 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Doxorubicin Hydrochloride
Doxorubicin Hydrochloride · DOXORUBICIN HYDROCHLORIDE 2 mg/mL · Injectable, Liposomal · Intravenous · BluePoint Laboratories
NDC 68001-0345-26 · 1 VIAL, SINGLE-DOSE in 1 CARTON / 25 mL in 1 VIAL, SINGLE-DOSE · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$1,937.50
Reported to Texas DSHS · 2025 annual filing · Blue Point Laboratories
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicare Part B (ASP)
Payment limit per 10 MG
$116.605
HCPCS Q2050 · Jul 1, 2026 quarter · typically ASP + 6%
Medicaid spend (2023)
$3,660
12 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- Natco Pharma LimitedIndiaanalysis · manufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- ANDA208657
- TE code
- AB
- Approval date
- May 15, 2017
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Doxorubicin Hydrochloride (Injectable, Liposomal)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| BluePoint Laboratories | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| NorthStar RxLLC | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Sun Pharmaceutical Industries, Inc. | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Zydus Pharmaceuticals USA Inc. | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Zydus Lifesciences Limited | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Aug 31, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Doxorubicin Hydrochloride — NDC 68001-0345-26," retrieved September 3, 2026, https://drugdashboards.com/drug/68001034526.
Free to cite with attribution — see how the data is put together.